Cardlytics (NASDAQ:CDLX) Stock Rating Upgraded by Northland Capmk

Cardlytics (NASDAQ:CDLX) was upgraded by stock analysts at Northland Capmk to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks.com reports.

CDLX has been the topic of a number of other reports. Craig Hallum reduced their target price on shares of Cardlytics from $18.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of Cardlytics in a research note on Tuesday, June 11th. Lake Street Capital upped their price objective on shares of Cardlytics from $13.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Finally, Northland Securities assumed coverage on shares of Cardlytics in a research note on Tuesday. They set an “outperform” rating and a $14.00 price objective for the company. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $13.00.

Cardlytics Price Performance

NASDAQ:CDLX opened at $8.21 on Tuesday. The firm has a market cap of $400.24 million, a price-to-earnings ratio of -1.86 and a beta of 1.67. The company has a current ratio of 2.13, a quick ratio of 2.13 and a debt-to-equity ratio of 1.30. The company’s 50-day moving average is $10.64 and its two-hundred day moving average is $9.57. Cardlytics has a 12-month low of $5.53 and a 12-month high of $20.52.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Wednesday, May 8th. The company reported ($0.35) earnings per share (EPS) for the quarter. The firm had revenue of $67.61 million during the quarter. Cardlytics had a negative net margin of 55.23% and a negative return on equity of 25.36%.

Insider Buying and Selling

In related news, CEO Karim Saad Temsamani sold 43,129 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.65, for a total transaction of $373,065.85. Following the completion of the sale, the chief executive officer now owns 385,530 shares of the company’s stock, valued at approximately $3,334,834.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, major shareholder Clifford Sosin acquired 3,746 shares of the stock in a transaction on Monday, May 13th. The stock was bought at an average price of $8.99 per share, with a total value of $33,676.54. Following the completion of the transaction, the insider now directly owns 6,464,859 shares of the company’s stock, valued at $58,119,082.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Karim Saad Temsamani sold 43,129 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.65, for a total transaction of $373,065.85. Following the completion of the sale, the chief executive officer now directly owns 385,530 shares of the company’s stock, valued at approximately $3,334,834.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,435 shares of company stock valued at $828,269. 4.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cardlytics

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Cardlytics by 13.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,011,705 shares of the company’s stock valued at $33,193,000 after buying an additional 231,303 shares during the last quarter. General Equity Holdings LP boosted its stake in shares of Cardlytics by 31.0% during the 4th quarter. General Equity Holdings LP now owns 624,058 shares of the company’s stock valued at $5,748,000 after buying an additional 147,843 shares during the last quarter. Clear Street Markets LLC purchased a new position in shares of Cardlytics during the 4th quarter valued at approximately $199,000. Invesco Ltd. boosted its stake in shares of Cardlytics by 538.1% during the 3rd quarter. Invesco Ltd. now owns 803,241 shares of the company’s stock valued at $13,253,000 after buying an additional 677,354 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in shares of Cardlytics by 27.5% during the 3rd quarter. LPL Financial LLC now owns 424,150 shares of the company’s stock valued at $6,998,000 after buying an additional 91,400 shares during the last quarter. 68.10% of the stock is currently owned by hedge funds and other institutional investors.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.